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Abstract Congenital nephrotic syndrome (CNS) is a rare
kidney disorder characterized by heavy proteinuria, hypo-
proteinemia, and edema starting soon after birth. The
majority of cases are caused by genetic defects in the
components of the glomerular filtration barrier, especially
nephrin and podocin. CNS may also be a part of a more
generalized syndrome or caused by a perinatal infection.
Immunosuppressive medication is not helpful in the genetic
forms of CNS, and kidney transplantation is the only
curative therapy. Before the operation, management of
these infants largely depends on the magnitude of protein-
uria. In severe cases, daily albumin infusions are required to
prevent life-threatening edema. The therapy also includes
hypercaloric diet, thyroxin and mineral substitution, pre-
vention of thrombotic episodes, and prompt management of
infectious complications. The outcome of CNS patients
without major extrarenal manifestations is comparable with




Congenital nephrotic syndrome (CNS) is defined as heavy
proteinuria starting within three months after birth. Ne-
phrotic syndrome (NS) appearing later during the first year
(4–12 months) is defined infantile, and NS manifesting
thereafter is called childhood NS [1, 2]. These definitions
have been used for decades in order to help the clinical
diagnosis, although recent findings indicate that NS caused
by a particular gene defect can manifest at various ages,
questioning the rationale of the classification. Since the
overall etiology, clinical features and management of CNS,
however, are different from the more common forms of
childhood NS, the terminology still seems warranted
(Table 1).
Glomerular filtration barrier
The cardinal feature of CNS is the extensive leakage of
plasma proteins into urine. In most cases, this is caused by
mutations in genes encoding for structural or regulatory
proteins of the kidney filtration barrier located in the
glomerular capillary wall [3–5]. This filter is composed of
three layers: fenestrated endothelium, glomerular basement
membrane (GBM), and epithelial cell (podocyte) layer with
distal foot processes and interposed slit diaphragms (SD)
(Fig. 1). The barrier is an effective size- and charge-
selective molecular sieve, and normally only water and
small plasma solutes pass through it. The flux of albumin
and larger plasma proteins is restricted by the GBM and
especially SD, so that the protein content of the ultrafiltrate
(primary urine) reaching the Bowman space is very low.
The GBM’s role in glomerular permselectivity has been
debated recently, but it is now known that proteinuria can
be caused by a primary defect in either SD or GBM.
The GBM is a well-known protein network formed by
type IV collagen, laminin, nidogen, and negatively charged
proteoglycans. On the other hand, the precise molecular
structure of the SD is still unresolved. Recently identified
podocyte proteins, such as nephrin, Neph1, Neph2, FAT1,
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e-mail: hannu.jalanko@hus.fiFAT2, and dendrin probably form the backbone of SD [6–
8]. These proteins associate with each other extracellularly
and interact with the adapter proteins, such as podocin,
CD2AP, ZO-1, CASK, and MAGI-1, localized in the
cytosolic part of the podocyte. These connect SD with the
actin cytoskeleton of the podocyte foot process and take
part in signal transduction from the slit diaphragm area into
podocyte [9]. Actin network and the interacting proteins,
such as α-actinin-4, are critical for maintenance of the
complex structure of the podocyte. Interestingly, this
molecular organization becomes disrupted in CNS and
other proteinuric disorders, leading to effacement of
podocyte foot processes.
Different forms of CNS
Nephrin gene (NPHS1) mutations
Mutations in NPHS1 gene cause CNS, which was originally
named as the Finnish type of CNS, or CNF [10]. Since CNF
originally referred to a clinical entity (severe form of CNS),
an abbreviation of NPHS1 (nephrotic syndrome type 1) was
introduced to specify those cases known to be caused by
NPHS1 mutations [10]. In practice, both terms are used for
the same disorder. The incidence of NPHS1 is one in 8,000
live births in Finland, and about half of the published cases
are Finns. Currently, close to 100 mutations in the NPHS1
gene have been identified [11–13]. Most patients have
individual mutations of different types, except in Finland,
where two founder mutations (Fin-major and Fin-minor) are
detected in almost all cases. NPHS1 codes for nephrin,
which is a 1241-residue transmembrane adhesion protein of
the immunoglobulin superfamily (Fig. 1). Nephrin is
synthesized almost exclusively by glomerular podocytes
and is a crucial component of the SD, as noted above.
Compared with many other genetic disorders, NPHS1
shows relatively little phenotypic variation [14]. Most of
these children are born prematurely, with a birth weight
ranging between 1,500 and 3,500 g. The placental weight is
over 25% of the newborn weight in practically all cases.
Amniotic fluid may be meconium stained, but the infants
do not usually have major respiratory problems. Impor-
tantly, NPHS1 infants do not have extrarenal malforma-
tions. On the other hand, minor functional disorders, such
as muscular hypotonia and cardiac hypertrophy, are
common during the nephrotic stage. Proteinuria begins in
utero and is detectable in the first urine sample after birth.
Microscopic hematuria and normal creatinine values during
the first months are typical. Heavy protein loss (up to
Table 1 The etiology of congenital nephrotic syndrome (CNS)
Primary CNS
Nephrin gene mutations [NPHS1, Finnish type of CNS (CNF)]
Podocin gene mutations (NPHS2)
WT1 gene mutations (Denys-Drash, isolated CNS)
LamB2 gene mutations (Pierson syndrome, isolated CNS)
PLCE1 gene mutations
LMX1B mutations (nail-patella syndrome)
LamB3 gene mutations (Herlitz junctional epidermolysis bullosa)
Mitochondrial myopathies





Cytomegalovirus, rubella, hepatitis B, HIV
Maternal systemic lupus erythematosus
Neonatal autoantibodies against neutral endopeptidase
Maternal steroid–chlorpheniramine treatment
Fig. 1 Cross-section of a glomerular capillary (left) and electron
microscopy image of a normal capillary wall (right). WT1 is a
transcription factor important for podocyte function. Nephrin is a
major component of the slit diaphragm (SD) connecting podocyte foot
processes. Podocin is an adapter protein located intracellularly in the
SD area. Laminin is a major structural protein of the glomerular
basement membrane (GBM). Genetic mutations in these proteins lead
to congenital nephrotic syndrome
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Hyperlipidemia is also present, as in other forms of NS.
The NPHS1 kidneys are large and in ultrasound scans
cortical echogenicity is increased, and the corticomedullary
border is indistinct. In renal histology, no single histological
finding is pathognomonic for NPHS1. Expansion of
glomerular mesangium and dilations in the proximal and
distal tubules are the most characteristic findings. Interstitial
fibrosis and inflammatory infiltrates, especially around the
glomeruli, increase with time. Effacement of podocyte foot
processes and disappearance of the filamentous image of
SD are seen in electron microscopy [14].
Podocin gene (NPHS2) mutations
Mutations in the NPHS2 gene, encoding for a podocyte
protein podocin, are a common cause of childhood (steroid-
resistant) NS, but they are also important in the develop-
ment of CNS [11–16]. In a recent report, NPHS2 mutations
accounted for half of the CNS cases in 80 European
families, while NPHS1 mutations were responsible for only
one third of the cases [17]. The NPHS2 mutations have also
been found in CNS patients from Japan and elsewhere.
They are typically “severe”, leading to nonfunctional
podocin protein (often truncated). Since podocin is a
podocyte-adapter protein required for proper targeting of
nephrin into SD, nephrin expression also may be distorted
in CNS caused by NPHS2 mutations (Fig. 1)[ 18].
Coexistence of NPHS1 and NPHS2 mutations has been
reported in CNS patients, but the clinical significance of
this is not clear [11, 19].
No systematic analysisof clinicalfindingsin CNSpatients
with NPHS2 mutations has been published. The severity of
proteinuria and, thus, the clinical findings are more variable
than in NPHS1 patients [16]. The kidney histology often,
but not exclusively, shows focal and segmental glomerular
sclerosis (FSGS). Patients develop end-stage renal disease
(ESRD) at the age of a few years [17]. Podocin is only
expressed in kidney glomerulus, and no major extrarenal
manifestations are present. As is the case in NPHS1, minor
cardiac problems have been reported.
Other genetic forms
Wilms’ tumor suppressor gene (WT1) encodes for a
transcription factor WT1, which plays a crucial role in the
embryonic development of the kidney and genitalia
(Fig. 1). It is abundantly expressed in podocytes and
controls cellular functions, such as nephrin expression.
Mutations in WT1 may cause several types of developmen-
tal syndromes (Denys-Drash, Frasier, and WAGR syn-
dromes) manifesting in childhood [20–22]. WT1 mutations
can also cause an isolated kidney disease, with NS
appearing in the first 3 months of life [17, 23]. They
account for a few percent of CNS cases. Patients may have
moderate proteinuria, and renal biopsy most often reveals
diffuse mesangial sclerosis (DMS) of glomeruli.
A new genetic entity comprising CNS and distinct ocular
anomalies with microcoria as the leading clinical feature
(Pierson syndrome) was described in 2004 [24]. The
disorder is caused by mutations in the laminin-β2 gene
(LAMB2). Laminin-β2 is a component of GBM, where it is
crucial for the network structure and anchoring of GBM to
podocyte foot processes (Fig. 1). Interestingly, this was the
first clear evidence that genetic defects in the GBM
components can cause CNS in humans. Later studies
revealed that the spectrum of LAMB2-associated disorders
is broader than first suggested, and CNS patients without
eye involvement have been described [25].
Galloway-Mowat syndrome (GMS) is characterized by
NS with central nervous system anomalies, including
microcephaly, psychomotor retardation, and brain anom-
alies [26]. Other extrarenal disorders, such as hiatus hernia,
dysmorphic features, shortness, and diaphragmatic defects,
have also been reported [2]. NS appears usually at the age
of a few months (0–34 months), and kidney biopsy may
show only minor changes [minor-change nephrotic syn-
drome (MCNS)], FSGS, or DMS. GMS is an autosomal
recessive disorder, but the genetic defect(s) is still
unknown. Podocytes resemble neuronal cells and share
many structural proteins. Thus, genetic syndromes affecting
both kidney and central nervous system are not surprising.
In addition to GMS, there are reports on other, unique,
combinations of NS and extrarenal defects, including CNS-
associated mitochondrial cytopathy [27], nail-patella syn-
drome [28], congenital disorder of glycosylation type I
[29], Herlitz junctional epidermolysis bullosa [30], and
CNS caused by mutations in the phospholipase C epsilon
gene (PLCE1)[ 31].
Nongenetic forms
Genetic defects account for the great majority of CNS
cases, but especially in developing countries, infections are
a possible etiology. Congenital syphilis has long been
known to cause nephritic or nephrotic syndrome in the
newborn [32]. Proteinuria and hematuria are present, but
severe NS is less common. Kidney biopsy shows membra-
nous nephropathy. Antimicrobial therapy with penicillin is
curative provided that irreversible renal lesions have not
developed. Toxoplasmosis, congenital rubella, and hepatitis
B virus infection may also cause CNS. HIV can also infect
kidney (podocytes) and is associated with nephropathy,
includingNS.Itusuallyappearsinchildrenolderthan1year,
but affected infants have been reported. An association of
neonatal cytomegalovirus infection (CMV) and CNS has
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the first weeks of life, and detection of this virus in an
infant with NS does not exclude an underlining genetic
defect. This should be searched especially if ganciclovir
therapy is not helpful. In addition to infections, CNS has
been associated with maternal systemic lupus erythemato-
sus and more recently with neonatal alloimmunization
against neutral endopeptidase present on podocytes [34].
Diagnosis of CNS
In severe forms of CNS, generalized edema, urinary protein
> 20 g/L, and serum albumin level <10 g/L can be detected in
the newborn period. The amount of proteinuria, however,
varies in different entities, and the clinical signs may not be
evident during the first weeks of life. Also, the true magnitude
of proteinuria may be detectable only after partial correction
of hypoproteinemia by albumin infusions. Small amounts of
red blood cells and leucocytes are often present in urine.
Serum creatinine and urea levels are variable. Renal function
remains quite normal for the first months in NPHS1, but in
otherforms,kidneyfailuremaydevelopfaster.Bloodpressure
values can be low due to hypoproteinemia or elevated if renal
failure is already present.
In newborns, the placental weight >25% of birth weight
is present in NPHS1 but may be seen in other forms of
CNS [14]. The kidneys may be of normal size or larger than
normal in ultrasound scanning, and the renal cortex is often
hyperechogenic. Search for possible nonrenal malforma-
tions is important, especially since they may give clues to
the etiologic diagnosis. These include genital abnormalities
(WT1), eye defects (LAMB2), and neurological disorders
(Mowat–Galloway). Cardiac evaluation often reveals ven-
tricular hypertrophy but no structural defects.
Renal biopsy does not reveal the etiology of CNS. As
pointed out, the genetic defects may cause several types of
glomerular lesions, such as mesangial expansion, FSGS,
MCNS, and DMS, and the findings overlap in different
entities. Also, the nonglomerular findings, such as tubular
dilatations and interstitial fibrosis and inflammation, can be
seen in all forms of proteinuric diseases. Thus, the
indications for renal biopsy are not quite clear. The
knowledge of severity of glomerular sclerosis and intersti-
tial fibrosis may help in the assessment of treatment
strategies. On the other hand, the lesions are focal, and
the biopsy findings may be misleading. If immunohisto-
chemistry for nephrin and podocin is available, analysis of
their expression in a biopsy sample is useful. Total lack of
either protein speaks for a severe disorder not responding to
antiproteinuric therapy.
Genetic analysis is the method of choice for precise CNS
diagnosis. The knowledge of etiology helps in assessing
management and prognosis, in follow-up for possible
associated symptoms, and in genetic counseling of the
family. Analysis of NPHS1 and NPHS2 mutations is
warranted in all CNS patients. These analyses are commer-
cially available in Athena Diagnostics (www.athenadiag
nostics.com). If no mutations are detected in these genes or
if clinical findings speak for mutations in WT1 or LAMB2
gene, analysis of these genes can be obtained at research
laboratories.
Prenatal diagnosis in families with a known risk for CNS
should be based on genetic testing whenever possible. The
results can be obtained fast if the mutations are known in
advance. In case of no family history or if the mutations in
the affected child were not identified, prenatal genetic
testing is a challenge, since sequencing the NPHS1 (29
exons) and NPHS2 (eight exons) genes is time consuming
and usually not possible within the short time frame
available. NPHS1 especially can still be suspected prena-
tally based on elevated alpha-fetoprotein (AFP) levels in
maternal serum and amniotic fluid. If the AFP concentra-
tion in amniotic fluid is very high and the ultrasound
examination does not reveal fetal anencephaly or other
malformations, NPHS1 is a probable diagnosis. However,
heterozygous fetal carriers of NPHS1 gene mutations may
have temporarily elevated AFP levels in amniotic fluid and
maternal serum, and repeated measurement of amniotic
fluid AFP before the 20th week of pregnancy is recom-
mended in cases with high AFP levels [35].
CNS management
In contrast to most cases of childhood NS, therapy with
steroids or other immunosuppressive drugs does not bring
CNS into remission. The goals of therapy during the first
months are to control edema and possible uremia, prevent
and treat complications such as infections and thromboses,
and provide optimal nutrition so that the child grows and
develops as normally as possible (Table 2). In most cases,
kidney transplantation is the only curative treatment.
Albumin infusions
The magnitude of the protein losses into urine is crucial for
therapeutic decision making. Heavy and constant protein-
uria (10–100 gr/L) inevitably leads to life-threatening
edema, protein malnutrition, reduced growth, and second-
ary complications. In these cases, protein substitution by
parenteral albumin infusions is mandatory. Our practice in
treating NPHS1 patients is to infuse 20% albumin solution
together with a bolus of intravenous furosemide (0.5 mg/kg)
using central venous catheters. The substitution is first
divided into three 2-h infusions (starting dose 1–5 ml/kg per
2124 Pediatr Nephrol (2009) 24:2121–2128infusion) and after a few weeks given as one 6-h infusion
during the night (up to 15–20 ml/kg each night; 3–4 g/kg of
albumin). This substitution corrects hypoproteinemia only
temporarily, but the patients do not have substantial edema.
Medications
A reduction in the protein excretion using angiotensin-
converting enzyme (ACE) inhibitors and indomethacin may
be obtained in some infants with CNS [36]. Patients with
severe NPHS1 or NPHS2 mutations inhibiting nephrin and
podocin expression (stop codons, deletions, missense muta-
tions) do not respond to this therapy, but in other cases,
treatment with “antiproteinuric” medication is worth trying.
Due to the protein excretion, patients with NS often have
low levels of serum thyroid-binding globulin and thyroxine.
Thyroid-stimulating hormone (TSH) may be normal in the
beginning but typically increases during the first months.
Thus, thyroxine substitution is recommended in CNS
patients. The medication can be started with 6.25–12.5
μg/day, and the dose can be adjusted according to TSH
levels. Urinary protein losses result in imbalance of plasma
coagulation factor levels, contributing to hypercoagubility
and risk for thromboses. Thus, the use of aspirin and
dipyridamole therapy has been recommended. Finnish
NPHS1 patients are successfully treated with sodium
warfarin from 3–4 weeks of age. Before surgical or vascular
procedures, warfarin is stopped, and antithrombin III
(50 IU/kg) is given to temporarily correct the deficiency.
Because of urinary losses of gamma globulin and
complement factors and the use of indwelling catheters,
nephrotic infants are prone to bacterial infections. Prophy-
lactic use of antibiotics has been recommended, but in our
experience, it is not helpful and only induces resistant
bacterial strains. Similarly, prophylactic use of immuno-
globulin infusion does not reduce the incidence of bacterial
infections. On the other hand, a high degree of suspicion for
septic infections is warranted. The symptoms are often
vague and masked by signs of focal infections occurring at
the same time. Parenteral antibiotic therapy should be
started promptly on suspicion and should cover the major
hospital strains of bacteria. Intravenous immunoglobulin is
used along with the antibiotics in some centers. Response to
treatment even in septic infection is usually excellent.
Nutrition
Infants with severe CNS have traditionally been treated
with a high-energy (130 kcal/kg per day) and a high-protein
(3–4 g/kg per day) diet. Breast milk and milk formulas are
first used, and the excess protein is given as a casein-based
protein product. Glucose polymers are given to increase
energy intake, and a mixture of rapeseed and sunflower oil
is given to balance lipid levels [2]. The children also
receive vitamin D2 (400 IU/day), which is changed to
alpha-calcidiol when an increase of parathyroid hormone
level is noticed. Multivitamin preparations are given
according to the recommended dietary allowances for
healthy children of the same age. Supplementary magne-
sium (50 mg/day) and calcium (500–1,000 mg/day) are also
given to keep serum levels within the normal range. Daily
water intake is 100–130 mL/kg. Most patients need a
nasogastric tube to guarantee their energy intake.
Nephrectomy
Some centers have a routine of performing unilateral
nephrectomy to reduce protein losses [37]. This may
decrease the frequency of the albumin infusions and help
in the everyday management, so that renal transplantation
can be postponed to an older age. Another approach is to
perform an early bilateral nephrectomy and start peritoneal
dialysis to avoid the complications encountered during the
nephrotic stage. Our practice in treating NPHS1 patients is
to perform bilateral nephrectomy when the child weighs
about 7 kg and start peritoneal dialysis, which allows the
infant stay at home. Renal transplantation is then performed
a few months later when the child weighs more than 9 kg
and the extraperitoneal placement of the graft is possible.
The third possibility is to perform an early, preemptive
renal transplantation with an intraperitoneal placement of
the kidney graft. In this case, the nephrotic kidneys are
removed at the same operation.
Kidney transplantation
Renal transplantation has become an established mode of
therapy for most children with CNS. The fact that CNS
children are often transplanted at 1–2 years of age using
Table 2 CNS management of infants with heavy proteinuria
Protein substitution parenterally
20% albumin infusions (3–4 g/kg per day of albumin)
Nutrition
Hypercaloric diet (130 kcal/kg per day)
Protein supplementation (4 g/kg per day)
Lipid supplementation (rapeseed/sun flower oil)
A, D, E and water soluble vitamins
Calcium and magnesium supplementation
Medication
Antiproteinuric drugs (ACE-inhibitor, indomethacin)
Thyroxin supplementation
Anticoagulation (warfarin, aspirin, ATIII-infusion)
Parenteral antibiotics when bacterial infection suspected
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and increase the risk for thrombotic and ureteral complica-
tions compared with older recipients. Postoperatively,
abundant hydration of the recipient (3,000 ml/m
2)i s
necessary to maintain optimum aortic and renal artery
blood flow and avoid low-flow states that could damage the
graft [38]. The use of immunosuppressive medication
should be balanced in order to prevent rejection episodes,
which may be clinically subtle, and on the other hand,
avoid the many side effects associated with these drugs.
Recurrence of NS in the graft is rare but has occurred in
some NPHS1 children who developed antinephrin anti-
bodies after transplantation. Treatment of the recurrence
with cyclophosphamide and plasmapheresis often leads to
remission [39].
Overall, the results of kidney transplantation in CNS are
quite good and similar to those obtained in other etiologies.
Patient survival at 5 years is over 90% and graft survival
over 80% in registry databases and in single centers [40,
41]. Chronic allograft nephropathy, however, is a major
problem also in these patients, and a second transplantation
is inevitable when the patients become young adults.
Conclusions
During the past few years, our knowledge on the genetic
and molecular basis of CNS has greatly increased.
Podocyte proteins play an important role in glomerular
sieving, and mutations in genes encoding for nephrin,
podocin, WT1 and lamininβ2 account for most cases of
CNS. It is to be expected that more genetic defects will be
found in CNS patients in the near future. Also, management
of these infants has improved so that the outcome of CNS
patients is very similar to other pediatric kidney patients
requiring renal transplantation.
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Questions (Answers appear following the reference list)
1. The cardinal findings in CNS are:
a. Heavy proteinuria, high serum creatinine, and low
serum cholesterol
b. Heavy proteinuria, low serum albumin, and gener-
alized edema
c. Macroscopic hematuria, heavy proteinuria, high
blood pressure values
2. The two most important structures preventing protein-
uria in the kidney are:
a. Glomerularendothelialcellsandbasementmembrane
b. Glomerular endothelial and epithelial cells
c. Podocyte slit diaphragm and glomerular basement
membrane
3. The two most important genes associated with CNS
are:
a. Nephrin (NPHS1) and podocin (NPHS2) genes
b. WTI and LAMB2 genes
c. CD2AP and NEPH1 genes
4. CNS infants with heavy proteinuria have a risk for:
a. Bleeding episodes and hypertensive crisis
b. Thrombotic and septic episodes
c. Hyperthyroidism and hypermagnesemia
5. The effective treatment in most cases of CNS is:
a. Prednisone and other immunosuppressants
b. Calcium blockers and indomethacin
c. Renal transplantation
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